Noven Presents Pre-clinical Study Data at AAPS Annual Meeting

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) announced today that Noven scientists are presenting the results of four pre-clinical transdermal research projects today at the 2006 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. The full text of these poster presentations is available on Noven’s website at under "Research/Scientific Publications."

"The Noven research and development team continues to work to advance the science of transdermal drug delivery,” said Juan Mantelle, Noven’s Vice President and Chief Technical Officer. “Today's presentations represent a small portion of our development efforts, and reflect our commitment to expanding the universe of compounds that can be delivered transdermally."

At the AAPS meeting, Viet T. Nguyen, Noven Senior Scientist – Product Development, will present “The Use of Acrylic PSA Concentration, Permeation Enhancement and Backing Material Selection to Control the Drug Delivery of a Benzothiazole in Transdermal Drug Delivery Systems."

Mr. Nguyen also will present "In-Vitro Transdermal Delivery of Phentermine." Phentermine has been used as a short-term therapy (together with diet and behavior modification) to treat obesity.

Rod L. Hartwig, Noven Research Scientist, will present "Transdermal Drug Delivery of Polar Derivatives of Ketoprofen Free Acid Through Human Cadaver Skin." Ketoprofen is an NSAID therapy that has been used in the treatment of inflammation and pain caused by arthritis and other factors.

David Kanios, Noven's Director – Research & Development, will present "The Effect of Primary and Secondary Packaging Materials on the Stability of Drug-In-Adhesive Transdermal Drug Delivery Systems."

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven’s prescription patches are approved in over 30 countries and include Vivelle-Dot™ (the most prescribed estrogen patch in the U.S.) and Daytrana™ (the first and only patch approved for the treatment of ADHD). A range of new patches is under development by Noven in collaboration with industry partners. See for additional information.

Except for historical information contained herein, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve substantial risks and uncertainties. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the current expectations of Noven and are subject to a number of risks and uncertainties that are subject to change based on factors which are, in many instances, beyond Noven's control. These risks and uncertainties include the possibility that the compounds referenced in this press release may not advance beyond pre-clinical development. For additional information regarding these and other risks associated with Noven’s business, readers should refer to Noven’s Annual Report on Form 10-K for the year ended December 31, 2005 as well as other reports filed from time to time with the Securities and Exchange Commission.

Investors & Media
Joseph C. Jones
Vice President – Corporate Affairs

Business Development & Licensing
Pavan Handa
Vice President – Business Development